Abstract 37P
Background
Chemotherapy, as one of the main therapies to treat breast cancer, may result in undesirable side effects. It may disrupt the haematological system and cause disorders as a result of chemotoxicity. This condition may lead to a declining in Quality of Life (QoL) of the patients. There were limited data reported from Indonesia about the correlation between haematological chemotoxicity and QoL. Thus, the aim to find the association between them.
Methods
This was a cohort-prospective study which includes 50 breast cancer patients who undergone first-cycle of chemotherapy. Patients who had haematological abnormalities and poor quality of life before chemotherapy were excluded. Patient’s QoL was measured by QLQ-BR23 questionnaire which includes body image (BI); sexual functioning (SF); sexual enjoyment (SE); future perspective (FP); and functional total (FT). Haematological chemotherapy toxicity was determined by the number of haemoglobins, leukocytes count and platelet count. Chemotherapy toxicity is graded from 0 (no toxicity) to 5 (death) according to the National Common Institute Common Terminology Criteria for Adverse Events. Correlation is analysed with Pearson Correlation using SPSS version 25.0.
Results
65 patients were included in this study (mean age 46.98 ± 9.05). The correlation between haematological chemotoxicity and BI; SF; SE; FP; and FT were described as follow: Hb r = -0,3; -0.251; -0.498; -0.345; and -0.61 respectively, with p = 0.08; 0.044; 0.01; 0.283; and 0.02 respectively. Leukocyte r = -0.41; -0.121; -0.128; -0.7; -0.3 respectively, with p = 0.01; 0.3; 0.3; 0.02; 0.05 respectively. Platelet r = -0.123; -0.31; -0.7; -0.9; -0.042 respectively, with p = 0.3; 0.03; 0.04; 0.1; 0.05 respectively.
Conclusions
We found that Hb and platelet level is significantly correlated with sexual functioning, sexual enjoyment, and functional total. Meanwhile, the leukocyte level is significantly correlated with body image, future perspective, and functional total.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session